Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Return on Retained Earnings (RORE) is an indicator of a company's growth potential, it shows how much a company earns by reinvesting its retained earnings, i.e. profits after dividend payments.
Phibro Animal Health's 5-Year RORE % for the quarter that ended in Mar. 2026 was 27.50%.
The industry rank for Phibro Animal Health's 5-Year RORE % or its related term are showing as below:
PAHC's 5-Year RORE % is ranked better than 78.8% of 882
companies
in the Drug Manufacturers industry
Industry Median: 1.34
vs PAHC: 27.50
Phibro Animal Health (NAS:PAHC) 5-Year RORE % Explanation
Return on Retained Earnings (RORE) is important to investors because it reveals a company's efficiency and growth potential. A higher RORE indicates a higher return. A high RORE indicates that the company should reinvest profits into the business. A lower RORE suggests that the company should distribute profits to shareholders by paying out dividends, since those dollars aren't generating much additional growth for the company.
There are a several different ways to arrive at the Return on Retained Earnings. The simplest way to calculate it is by using published information on Earnings per Share (EPS) and Dividend per Share (DPS) over a selected period. Here, 5-year period is chosen.
Be Aware
Please keep in mind that the RORE is relative to the nature of the business and its competitors. If another company in the same sector is producing a lower return on retained earnings, it doesn’t necessarily mean it’s a bad investment. It may just suggest the company is older and no longer in a high growth stage. At such a stage in the business cycle, it would be expected to see a lower RORE and higher dividend payout.
Phibro Animal Health 5-Year RORE % Related Terms
Phibro Animal Health 5-Year RORE % Historical Data
* Premium members only.
The historical data trend for Phibro Animal Health's 5-Year RORE % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
PAHC vs PRGO, HROW, XERS: 5-Year RORE % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Phibro Animal Health's 5-Year RORE %, along with its competitors' market caps and 5-Year RORE % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Phibro Animal Health 5-Year RORE % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Phibro Animal Health's 5-Year RORE % distribution charts can be found below:
* The bar in red indicates where Phibro Animal Health's 5-Year RORE % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of 5-Year RORE %, the most recent and first period EPS (Diluted) is the trailing twelve months (TTM) data ended in Mar. 2026 and 5-year before.
Phibro Animal Health (PAHC) has a 5-Year RORE % of 27.50 as of Mar. 2026. 5-Year RORE % shows how much a company earns by reinvesting its retained earnings in 5-year. View historical data on Phibro Animal Health and its competitors. According to the industry distribution chart, Phibro Animal Health ranks #187 out of 882 companies in the Drug Manufacturers industry, placing it in the top 21.2%.
Is Phibro Animal Health's 5-Year RORE % too high?
Phibro Animal Health's current 5-Year RORE % is 27.50. The Drug Manufacturers industry median 5-Year RORE % is 1.34. Phibro Animal Health's value of 27.50 is 1952.2% above this industry median. Based on the distribution chart, Phibro Animal Health ranks #187 out of 882 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Phibro Animal Health has a GF Score™ of 75/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Phibro Animal Health's 5-Year RORE % compare to PRGO and HROW?
According to the Drug Manufacturers industry distribution chart, Phibro Animal Health ranks #187 out of 882 companies for 5-Year RORE %. This places Phibro Animal Health in the top 21% of its industry — outperforming the majority of peers. The industry median 5-Year RORE % is 1.34. Phibro Animal Health's value of 27.50 is 1952.2% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 5-Year RORE % for a Drug Manufacturers company?
The median 5-Year RORE % among Drug Manufacturers companies is 1.34, based on 882 companies in the industry. Companies in the top quartile (top 25%) have a 5-Year RORE % significantly above this median, while those in the bottom quartile fall well below. However, 5-Year RORE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Phibro Animal Health's current 5-Year RORE % of 27.50 is 1952.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 5-Year RORE % mean?
A high 5-Year RORE % can signal that a stock is expensive relative to its fundamentals. 5-Year RORE % shows how much a company earns by reinvesting its retained earnings in 5-year. View historical data on Phibro Animal Health and its competitors. For the Drug Manufacturers industry, the median 5-Year RORE % is 1.34 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Phibro Animal Health's current 5-Year RORE % is 27.50. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Phibro Animal Health stock overvalued right now?
Based on GuruFocus' analysis, Phibro Animal Health (PAHC) is currently considered Modestly Overvalued. The stock's GF Value™ is $29.54, compared to a current price of $34.26 — trading 16% above its estimated fair value. The current 5-Year RORE % is 27.50 and 1952.2% above the Drug Manufacturers industry median of 1.34. Phibro Animal Health's overall GF Score™ is 75/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 5-Year RORE % calculated?
5-Year RORE % is calculated from a company's financial statements. For Phibro Animal Health (PAHC), the current 5-Year RORE % is 27.50 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Phibro Animal Health (PAHC) Overvalued in 2026?
Based on GuruFocus' analysis, Phibro Animal Health stock appears to be overvalued.
The current stock price of $34.26 is trading 16% above its estimated GF Value™ of $29.54.
GuruFocus considers Phibro Animal Health to be Modestly Overvalued.
Key valuation signals for PAHC:
5-Year RORE %: 27.50
GF Value™: $29.54 vs. price of $34.26 (16% above fair value)
Industry Position: 1952.2% above the Drug Manufacturers median (#187 of 882)
No single metric tells the full story. See the PAHC stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Phibro Animal Health Corp operates as a diversified animal health and mineral nutrition company. It develops, manufactures, and markets products for a range of food animals comprising poultry, swine, beef and dairy cattle, and aquaculture. The product portfolio of the company includes animal health products such as antibacterials, anticoccidials, nutritional specialty products and vaccines, and mineral nutrition products. The company operates through three segments, Animal Health, Mineral Nutrition, and Performance Products, of which key revenue is derived from the Animal Health segment which relates to the development, manufacturing, and marketing of antibacterials, nutritional specialty products, and vaccines. The entity sells its products in the U.S. and other international countries.
75GF Score
Get the complete analysis for PAHC
5-Year RORE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
PAHC has been successfully added to your 
